Drug Trial Radar · NCT01999218
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
Last checked: Nov 20, 2026Latest source record: Apr 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,326
Actual
Start
Dec 16, 2013
Primary completion
Apr 18, 2017
Study completion Apr 18, 2017
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Dec 3, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of the addition of ertugliflozin (MK-8835/PF-04971729) compared with the addition of glimepiride in participants with T2DM who have inadequate glycemic control on metformin. The primary hypothesis of this study is that after 52 weeks, the change from baseline in hemoglobin A1c (A1C) in participants treated with the addition of ertugliflozin 15 mg once daily is non-inferior compared with that in participants treated with the addition of glimepiride.
Conditions
- Type 2 Diabetes Mellitus
Interventions
Ertugliflozin 5 mgDrug
Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
Ertugliflozin 10 mgDrug
Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
GlimerpirideDrug
Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
Placebo to ErtugliflozinDrug
Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
Placebo to GlimepirideDrug
Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
MetforminDrug
Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
SitagliptinDrug
Open label, oral, once daily, rescue medication as required.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Hemoglobin A1C (A1C) at Week 52: Excluding Rescue ApproachTime frame: Baseline and Week 52
- Percentage of Participants Experiencing An Adverse Event (AE) Up to Week 106Time frame: Up to Week 106
- Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 104Time frame: Up to Week 104
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.